R&D channel feed – Endpoints News

R&D channel feed

ImmunoGen's new CEO retrenches, axing 65 staffers and looking to thin pipeline

9 years ago

Amgen beefs up cardio pipeline, adding a $673M RNAi deal with Arrowhead

9 years ago

Step two: Celgene grabs a $20M option, plots MS PhII for Abide’s cannabinoid drug

9 years ago

Novo Nordisk takes out the ax and aims at R&D, chopping 1,000 jobs

9 years ago

Genentech snares a PhI RAF inhibitor from Hanmi in $910M deal

9 years ago

FDA slaps a full clinical hold on Alcobra’s troubled lead drug for ADHD, Fragile X

9 years ago

Novartis, Amgen rack up their first PhIII success in a crowded CGRP migraine drug field

9 years ago

The 2nd PhIII schizophrenia study for Intra-Cellular drug is a disaster, shares shredded

9 years ago

Incyte’s IDO1 update on its Keytruda combo scores some positive reviews

9 years ago

Hub appeal: AstraZeneca is marshaling 350-plus R&D troops in new South San Francisco campus

9 years ago

Gearing up new partnerships, Boehringer gets an option to buy a new player in oncolytic viruses in $230M deal

9 years ago

Pilot crash crushes little Galectin’s share price after NASH study fails

9 years ago

Porges: Gilead’s hep C bash is winding down and it doesn’t have a cure for the hangover

9 years ago

Shire punts late-stage biosimilars of Humira and Enbrel back to Momenta, Coherus

9 years ago

Cancer biotech upstart grabs $18M round, sets out to master relapsed prostate cancer

9 years ago

Bristol-Myers Squibb brings Opdivo to a joint immuno-oncology program with Nektar’s new T cell amplifier

9 years ago

Amgen hit with a setback as Kyprolis fails a key frontline trial for multiple myeloma

9 years ago

Kite’s groundbreaking CAR-T hits key study goal, heads to the FDA

9 years ago

Array Bio surges on positive results for first stage of melanoma combo PhIII

9 years ago

3 for 3 in PhIII: GW Pharma racing to the FDA after bagging another late-stage epilepsy success

9 years ago

As politicians debate the priority review voucher program, the FDA is rooting for its demise

9 years ago

Lundbeck, Otsuka take the latest hit on Alzheimer’s as PhIII drug flops

9 years ago

Teva gets a mixed bag of PhIII data as it lines up against a (better?) Neurocrine rival for tardive dyskinesia

9 years ago

Gilead scraps a PhII/III study early as drug flops against ulcerative colitis

9 years ago

First page Previous page 317 318 319320321 322 323 Next page Last page